[
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.Funding Statement\nThe author(s) declare that financial support was received for the research and/or publication of this article.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The structured development process of cancer vaccines used in clinical trials for glioblastoma patients is illustrated in \nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The immune cascade initiated upon vaccine administration is depicted in \nFigure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The concurrent timelines below highlight key milestones in glioblastoma research and vaccine development, illustrating the progression of immunotherapeutic strategies from the late 19th century to the present (\nFigure 3\n) (9, 21, 25, 30, 34–50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The intricacies of these interactions are particularly pronounced in the context of brain tumors, where physiological barriers present additional challenges to vaccine efficacy (\nFigure 4\n).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Cancer vaccines comprise three main components: a tumor antigen, an immunological adjuvant, and a vehicle or carrier (\nFigure 5\n).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 1\n\nhttps://BioRender.com/e18j381, \nFigure 2\n\nhttps://BioRender.com/ovi03sx, \nFigure 3\n\nhttps://BioRender.com/m68z329, \nFigure 4\n\nhttps://BioRender.com/r46v528, \nFigure 5\n\nhttps://BioRender.com/o56h938.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  }
]